Fig. 3: Participant demographics and elicited AEs after DMAb administration. | Nature Medicine

Fig. 3: Participant demographics and elicited AEs after DMAb administration.

From: Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Fig. 3: Participant demographics and elicited AEs after DMAb administration.

a, Demographic characteristics of the 44 participants enrolled in the study, including age, sex (self-reported), race and ethnicity. b, Frequency and severity of elicited AEs considered related to the study product or administration procedure, reported within 7 days after administration. For each participant, only the most severe grade of each event type is shown. Events are grouped according to category (for example, local, systemic) and graded according to protocol-defined criteria (mild, moderate, severe).

Back to article page